Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Tarlatamab (Imdelltra, Amgen) demonstrated superior overall survival in small cell lung cancer

Written by | 10 Jun 2025

In the global, Phase 3 DeLLphi-304 clinical trial1 evaluating Imdelltra® (tarlatamab-dlle) treatment for patients with small cell lung cancer (SCLC) who progressed on or after a single line of platinum-based chemotherapy,… read more.

Breast cancer mortality lower among women with screening-detected tumors

Written by | 5 Jun 2025

Breast cancer detected by routine screening of women aged 40 years or older is associated with lower odds of advanced cancer, mastectomy, and breast cancer–related death compared with… read more.

European regulation needed to prevent the birth of children with inherited cancer-causing genetic mutation after sperm donation

Written by | 3 Jun 2025

A case in which a sperm donor was later found to be carrying a cancer-causing pathogenic variant in his gametes has highlighted the problems of regulating gamete donation… read more.

ASCO/EHA 2025: Novartis highlights new data on Kisqali, Pluvicto, Scemblix, and Fabhalta

Written by | 30 May 2025

Novartis will present data from 60 company or investigator sponsored abstracts that have the potential to change clinical practice, at the 2025 American Society of Clinical Oncology (ASCO)… read more.

Bristol Myers Squibb to present 80+ studies across 20+ cancers at ASCO 2025

Written by | 29 May 2025

Bristol Myers Squibb announced the presentation of data across its oncology portfolio and pipeline at the 2025 American Society of Clinical Oncology (ASCO®) Annual Meeting to be held May… read more.

Eli Lilly showcases Imlunestrant, Olomorasib, and ADC advancements at ASCO 2025

Written by | 28 May 2025

Eli Lilly and Company announced that data from studies of imlunestrant, an investigational oral selective estrogen receptor degrader (SERD), olomorasib, an investigational KRAS G12C inhibitor, LY4170156, an investigational antibody-drug… read more.

Astellas showcases long-term XTANDI and PADCEV data at ASCO 2025

Written by | 28 May 2025

Astellas Pharma Inc. will present 16 abstracts featuring new data across its approved cancer therapies at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (May 30… read more.

ASCO 2025: Bicycle Therapeutics highlights Nectin-4-Targeting BT8009 in bladder cancer

Written by | 27 May 2025

Bicycle Therapeutics plc, a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, announced the poster presentation of two… read more.

ASCO 2025: Merck presents broad oncology data across 12+ tumor types

Written by | 27 May 2025

Merck, a leading science and technology company, announced the presentation of new oncology data across more than 12 tumor types at the 2025 American Society of Clinical Oncology… read more.

BeiGene to present 23 abstracts at ASCO 2025, showcasing BRUKINSA and breast cancer pipeline

Written by | 26 May 2025

BeiGene, Ltd., a global oncology company that will change its name to BeOne Medicines Ltd.,  announced it will share 23 abstracts featuring new data across its hematology and solid… read more.

Jazz Pharmaceuticals receives CHMP positive opinion for Ziihera (zanidatamab) for the treatment of advanced HER2-positive biliary tract cancer

Written by | 26 May 2025

Jazz Pharmaceuticals plc announced that the Committee for Medicinal Products for Human Use (CHMP) of the EMA  has adopted a positive opinion recommending the conditional marketing authorization of… read more.

One-week breast cancer radiotherapy proven as safe and effective as standard three-week treatment in 4,000-patient study over 10 years

Written by | 25 May 2025

Presented at ESTRO 2025, which gathered a record attendance of 7,908 participants this week in Vienna, Austria, a 10-year study, involving over 4,000 UK patients, confirms that a one-week… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.